Vitamin D3 for Life

Live Enlightened

Article

VDR FokI, Receptor Expression and Linked Haplotypes: Evidence Synthesis

Previous related pageVDR FokI Polymorphism in Human Breast Cancer Cells: Study SummaryNext related pageVDR Tissue Distribution and Measurement Reliability: Evidence Synthesis
Study at a glance

What does the FokI vitamin D receptor variant change?

FokI is the name used for a common genetic difference that changes where production of the receptor protein begins. One form is three amino acids, the building blocks of proteins, shorter than the other.

Is the shorter vitamin D receptor always more effective?

No. Some laboratory experiments found a stronger response from the shorter form, while others found no clear difference in the functions tested. The result depends on the cells and measurements used.

How do other common vitamin D receptor variants differ from FokI?

Many are studied as markers of nearby genetic changes inherited together. They may be linked to differences in how much receptor is made, without changing the order of the protein’s building blocks. Their meaning depends on the exact group of variants and the tissue studied, so they cannot be ranked as universally good or bad.

Read the full article below ↓

Common variants in the vitamin D receptor gene are often presented as if each allele simply makes the receptor “better” or “worse.” The functional evidence does not support that kind of ranking. Different VDR variants affect different parts of receptor biology, and their effects depend on what is being measured. The strongest evidence for the common FokI variant concerns a genuine difference in translation start and receptor length, but experiments disagree about how consistently that structural difference changes receptor activity. The commonly studied BsmI, ApaI and TaqI markers raise a different problem: they sit in the 3′ region of the VDR gene and are often markers of linked haplotypes rather than isolated protein-changing variants.

The most defensible interpretation is therefore not that common VDR polymorphisms create a universal hierarchy of vitamin D responsiveness. Instead, they can modify receptor expression or cellular response in particular genetic, tissue and experimental contexts. That distinction matters when moving from vitamin D genetics to claims about actual receptor function.

FokI changes where VDR translation begins

FokI is the clearest common example of a VDR polymorphism with a direct coding consequence. The relevant sequence difference affects the first translation-initiation codon. When translation begins at the first available start site, the receptor is three amino acids longer; when that first site is lost, translation begins at the next start site and the resulting receptor is three amino acids shorter.

Arai and colleagues tested this directly in 1997. Proteins produced from the two cloned VDR forms differed in apparent molecular size, consistent with alternative translation initiation. In a vitamin-D-responsive reporter system in transfected HeLa cells, the shorter form produced about 1.7-fold greater transcriptional activation than the longer form. In the same paper, genotype was also examined in Japanese women: among the healthy premenopausal subgroup used for lumbar-spine bone-density analysis, the mm homozygotes had higher bone mineral density than the MM homozygotes. The cell experiment is the more direct functional evidence; the bone-density observation is an association and should not be treated as proof that the receptor-length difference alone caused the skeletal difference.

The FokI activity difference is not universal

A direct follow-up by Gross and colleagues is important because it did not reproduce a broad functional advantage for either receptor form. The investigators confirmed that the two proteins were distinguishable by size, then tested several separate components of receptor function. Ligand-binding affinity did not differ significantly. The two forms showed no detectable difference in DNA binding in electrophoretic mobility-shift assays. Dose-response experiments using vitamin-D-responsive reporters for 24-hydroxylase, osteocalcin and osteopontin produced indistinguishable transactivation ED50 values. Human fibroblasts carrying FF, Ff or ff genotypes also showed similar sensitivity to 1,25-dihydroxyvitamin D when induction of 24-hydroxylase mRNA was measured.

That null result does not prove that FokI is functionally irrelevant. Gross and colleagues explicitly noted that their methods could have missed smaller differences. More importantly, the experiments asked particular biochemical and transcriptional questions. A later cellular model produced a different pattern.

Alimirah and colleagues created stable MCF-7 breast-cancer cell clones expressing the long or short VDR form and measured several responses to 1,25-dihydroxyvitamin D. Growth inhibition was greater in cells expressing the shorter VDR form, CYP24A1 induction was 1.8-fold higher, and oestrogen-receptor-α downregulation was stronger. The two cell populations also differed in VDR protein stability and basal expression of several inflammatory genes. These experiments show that a common FokI difference can matter biologically in a defined cellular system. They do not establish a fixed percentage advantage for one genotype across healthy tissues, physiological vitamin D exposures or clinical outcomes.

Why positive and null FokI studies can coexist

The FokI literature makes sense once “receptor function” is separated into its component measurements. A receptor can show no detectable difference in ligand affinity or a classical reporter assay yet still produce a different downstream cellular response in another model. Cell type, promoter architecture, receptor abundance, co-regulators, dose, assay sensitivity and the particular response being measured can all influence what becomes visible experimentally.

That is why the structural fact and the functional conclusion must be kept separate. FokI genuinely changes VDR translation initiation and receptor length. What that difference does downstream is context-dependent. For a broader explanation of the receptor itself, see Vitamin D Receptors.

BsmI, ApaI and TaqI are a different kind of polymorphism problem

The commonly discussed BsmI, ApaI and TaqI variants are often grouped with FokI, but they should not be interpreted in the same way. FokI changes the translation start and therefore the length of the receptor protein. The traditional 3′-region markers do not automatically alter the amino-acid sequence of VDR. Their biological significance may instead come from linkage with other regulatory variation or from the behaviour of larger haplotypes that contain several linked variants.

Durrin and colleagues tested one proposed mechanism directly: whether common VDR 3′-untranslated-region haplotypes altered mRNA stability. They sequenced the VDR 3′UTR, identified common and rare variants, mapped destabilising elements, and then placed two common VDR 3′UTRs behind a heterologous β-globin reporter. The measured message half-lives were essentially identical: 5.3 ± 1.4 hours for one construct and 5.2 ± 0.4 hours for the other. None of the common variants they identified fell within the mapped destabilising elements. Under those experimental conditions, the common 3′UTR haplotypes did not provide evidence for different mRNA stability.

This is a useful null finding because it blocks a tempting shortcut. An epidemiological association involving a BsmI-linked or other 3′-region genotype cannot simply be explained by asserting that the allele makes VDR mRNA last longer or decay faster.

Defined VDR haplotypes can still alter expression

Fang and colleagues later examined VDR variation at a broader haplotype level in the Rotterdam Study. Their work combined population genetics with functional experiments. In 6,148 older white participants, defined promoter and 3′UTR haplotypes were associated with fracture risk. The functional experiments then tested whether the implicated haplotypes could alter gene expression.

The promoter risk haplotype produced 53% lower reporter expression in two cell lines. Constructs carrying a 3′UTR risk haplotype produced about 15% lower VDR mRNA across five cell lines, and in an osteoblast cell line the same risk haplotype showed a 30% increase in mRNA decay. These findings are not a simple reversal of Durrin. The two studies examined different sequence definitions, constructs and experimental contexts. Together they show why the exact haplotype matters: one set of common 3′UTR variants showed no difference in message half-life, while a later defined risk haplotype was associated with lower expression and faster decay.

Human tissue evidence adds another layer of context

Carling and colleagues studied VDR and parathyroid-hormone mRNA in 42 parathyroid adenomas from patients with sporadic primary hyperparathyroidism. Tumours carrying particular b, a and T allele patterns had lower VDR mRNA and higher PTH mRNA than comparison genotypes. When haplotypes were considered, baT tumours had lower relative VDR mRNA and higher PTH mRNA than non-baT tumours.

This is human tissue evidence that common VDR genetic patterns can correspond to differences in receptor expression and a biologically related downstream signal. It is also a strong example of why generalisation needs care. These were parathyroid adenomas, not a survey of healthy tissues. The study does not prove that an isolated BsmI, ApaI or TaqI marker directly controls VDR expression in every tissue, and it cannot establish that the same magnitude or direction of effect occurs throughout the body.

What the functional evidence supports

Across these studies, common VDR polymorphisms can influence receptor biology, but there is no defensible single “VDR efficiency” scale. FokI has a direct structural consequence because it changes translation initiation and receptor length. Some experiments report greater transcriptional or cellular response from the shorter form, while other carefully designed assays detect little or no difference. For common 3′-region variation, the functional unit may be a linked haplotype rather than an isolated restriction-site marker, and the observed effect can involve receptor expression rather than altered receptor chemistry.

The practical implication is one of precision. A VDR genotype can be biologically relevant without being deterministic. Its meaning depends on the exact variant or haplotype, the tissue and cell state, the molecular endpoint being measured, and the rest of the signalling system. That is why common VDR polymorphisms should be interpreted as potential modifiers of response, not as stand-alone measures of vitamin D function.

Primary evidence used in this synthesis

  • Arai H et al. A Vitamin D Receptor Gene Polymorphism in the Translation Initiation Codon: Effect on Protein Activity and Relation to Bone Mineral Density in Japanese Women. Journal of Bone and Mineral Research. 1997;12(6):915 to 921. DOI: 10.1359/jbmr.1997.12.6.915. View the primary study.
  • Gross C et al. The Vitamin D Receptor Gene Start Codon Polymorphism: A Functional Analysis of FokI Variants. Journal of Bone and Mineral Research. 1998;13(11):1691 to 1699. DOI: 10.1359/jbmr.1998.13.11.1691. View the primary study.
  • Durrin LK et al. Vitamin D receptor 3′-untranslated region polymorphisms: lack of effect on mRNA stability. Biochimica et Biophysica Acta. 1999;1453(3):311 to 320. DOI: 10.1016/S0925-4439(99)00007-1. View the primary study.
  • Fang Y et al. Promoter and 3′-Untranslated-Region Haplotypes in the Vitamin D Receptor Gene Predispose to Osteoporotic Fracture: The Rotterdam Study. American Journal of Human Genetics. 2005;77(5):807 to 823. DOI: 10.1086/497438. PMCID: PMC1271389. View the primary study.
  • Carling T et al. Vitamin D Receptor (VDR) and Parathyroid Hormone Messenger Ribonucleic Acid Levels Correspond to Polymorphic VDR Alleles in Human Parathyroid Tumors. Journal of Clinical Endocrinology & Metabolism. 1998;83(7):2255 to 2259. DOI: 10.1210/jcem.83.7.4862. View the primary study.
  • Alimirah F et al. Functional Significance of Vitamin D Receptor FokI Polymorphism in Human Breast Cancer Cells. PLoS ONE. 2011;6(1):e16024. DOI: 10.1371/journal.pone.0016024. PMCID: PMC3025916. View the primary study.

Related reading

Original sources

Source

View the primary study

Arai H et al. A Vitamin D Receptor Gene Polymorphism in the Translation Initiation Codon: Effect on Protein Activity and Relation to Bone Mineral Density in Japanese Women.

Publication details

Arai H et al. A Vitamin D Receptor Gene Polymorphism in the Translation Initiation Codon: Effect on Protein Activity and Relation to Bone Mineral Density in Japanese Women. Journal of Bone and Mineral Research. 1997;12(6):915 to 921. DOI: 10.1359/jbmr.1997.12.6.915. View the primary study.

Read more →
Source

View the primary study

Gross C et al. The Vitamin D Receptor Gene Start Codon Polymorphism: A Functional Analysis of FokI Variants.

Publication details

Gross C et al. The Vitamin D Receptor Gene Start Codon Polymorphism: A Functional Analysis of FokI Variants. Journal of Bone and Mineral Research. 1998;13(11):1691 to 1699. DOI: 10.1359/jbmr.1998.13.11.1691. View the primary study.

Read more →
Source

View the primary study

Durrin LK et al. Vitamin D receptor 3′-untranslated region polymorphisms: lack of effect on mRNA stability.

Publication details

Durrin LK et al. Vitamin D receptor 3′-untranslated region polymorphisms: lack of effect on mRNA stability. Biochimica et Biophysica Acta. 1999;1453(3):311 to 320. DOI: 10.1016/S0925-4439(99)00007-1. View the primary study.

Read more →
Source

View the primary study

Fang Y et al. Promoter and 3′-Untranslated-Region Haplotypes in the Vitamin D Receptor Gene Predispose to Osteoporotic Fracture: The Rotterdam Study.

Publication details

Fang Y et al. Promoter and 3′-Untranslated-Region Haplotypes in the Vitamin D Receptor Gene Predispose to Osteoporotic Fracture: The Rotterdam Study. American Journal of Human Genetics. 2005;77(5):807 to 823. DOI: 10.1086/497438. PMCID: PMC1271389. View the primary study.

Read more →
Source

View the primary study

Carling T et al. Vitamin D Receptor (VDR) and Parathyroid Hormone Messenger Ribonucleic Acid Levels Correspond to Polymorphic VDR Alleles in Human Parathyroid Tumors.

Publication details

Carling T et al. Vitamin D Receptor (VDR) and Parathyroid Hormone Messenger Ribonucleic Acid Levels Correspond to Polymorphic VDR Alleles in Human Parathyroid Tumors. Journal of Clinical Endocrinology & Metabolism. 1998;83(7):2255 to 2259. DOI: 10.1210/jcem.83.7.4862. View the primary study.

Read more →